One of the most recent paradigm shifts in the treatment of Lyme Disease has come in a growing recognition that while the condition has been treated as though it were an infection, it does not in fact behave as such. The real problem, and cause of illness symptoms in Lyme disease, is not the presence of these bacteria in the patient’s body, but rather the chronic immune activation against those organisms. As that is what makes the person ill.
People will become infected with these organisms (Borellia, Bartonella, Babesia, and possibly others) often long before chronic symptoms develop. It is only after the immune system decides to attack the bacteria that the symptoms and inflammation begin. There is often some inciting event that agitates the immune system and sets off this reaction; common examples include pregnancy and delivery, injury, illness, or great psychosocial stress.
LDI for Lyme disease offers an extremely effective, nontoxic, safe, inexpensive, and user-friendly means of treating this condition. The change in thinking involves switching from an “infection” model of Lyme disease to an “autoimmune disease” model. Through the use of LDI in this context, we are stopping the immune system from making auto antibodies against the tissues of the body and causing chronic Lyme symptoms.
While it is much more typical if dosing is accurate and appropriate for an individual, that symptoms will begin to improve the next day, or possibly several days or weeks after the treatment, clinicians have had also observed improvements literally within minutes. Nerve pain, tremors, and limb dysfunction have objectively improved before patients left the office.
If the dose given is too strong, the symptoms (whatever the individual symptoms of Lyme disease are) will typically flare up within 24-48 hours. These flares sometimes last just a few days, followed by dramatic improvement from their baseline or possibly just a return to their baseline. In other cases they have persisted greater than two weeks. Flare-ups are managed with anti-inflammatories and an adjustment of the subsequent dose to a lower concentration.